SEOUL PHARMA CO.,LTD: debt-to-equity, ROE and more
KOSDAQ, Legal name SEOUL PHARMA CO.,LTD
Latest figures are the FY2025 separate summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 74.8%
- Equity ratio
- 57.2%
- ROE
- 1.8%
- Op. margin
- -2.5%
- Rev. growth
- -2.7%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 1 straight year.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 separate | 228.4% | 30.5% | -51.1% | -14.1% | n/a |
| FY2022 separate | 76.2% | 56.7% | 2.4% | 3.5% | 23.7% |
| FY2023 separate | 64.2% | 60.9% | 9.1% | 2.3% | 4.8% |
| FY2024 separate | 78.3% | 56.1% | 4.2% | 2.9% | 2.1% |
| FY2025 separate | 74.8% | 57.2% | 1.8% | -2.5% | -2.7% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩40.5B | ₩50.1B | ₩52.5B | ₩53.6B | ₩52.1B |
| Operating profit | -₩5.7B | ₩1.7B | ₩1.2B | ₩1.5B | -₩1.3B |
| Pre-tax income | -₩9.6B | -₩1.1B | ₩4.0B | ₩1.8B | ₩631.6M |
| Net income | -₩9.7B | ₩855.1M | ₩3.5B | ₩1.7B | ₩753.6M |
| Total assets | ₩62.3B | ₩62.4B | ₩63.3B | ₩71.6B | ₩71.8B |
| Total liabilities | ₩43.3B | ₩27.0B | ₩24.7B | ₩31.4B | ₩30.7B |
| Total equity | ₩19.0B | ₩35.4B | ₩38.6B | ₩40.2B | ₩41.0B |
| Paid-in capital | ₩4.3B | ₩5.8B | ₩5.8B | ₩5.8B | ₩5.8B |
| Debt/equity (source value) | 228.4% | 76.2% | 64.2% | 78.3% | 74.8% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 1985-12-23
- Listed
- 00/08/18
- Employees
- 132
- Auditor
- 삼일회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1301110008721
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 서울제약Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.